{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:35:26Z","timestamp":1757543726646},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T00:00:00Z","timestamp":1280880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s00280-010-1420-z","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T06:15:47Z","timestamp":1280816147000},"page":"1137-1144","source":"Crossref","is-referenced-by-count":1,"title":["Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates"],"prefix":"10.1007","volume":"67","author":[{"given":"M.","family":"Joerger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"K\u00f6berle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. F.","family":"Riesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,4]]},"reference":[{"issue":"8","key":"1420_CR1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584\u2013593","journal-title":"Nat Rev Cancer"},{"issue":"4 Suppl 11","key":"1420_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0093-7754(01)90229-5","volume":"28","author":"N Janjan","year":"2001","unstructured":"Janjan N (2001) Bone metastases: approaches to management. Semin Oncol 28(4 Suppl 11):28\u201334","journal-title":"Semin Oncol"},{"key":"1420_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0305-7372(96)90021-3","volume":"22","author":"J Vinholes","year":"1996","unstructured":"Vinholes J, Coleman R, Eastell R (1996) Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22:289\u2013331","journal-title":"Cancer Treat Rev"},{"issue":"20 Pt 2","key":"1420_CR4","doi-asserted-by":"crossref","first-page":"6209s","DOI":"10.1158\/1078-0432.CCR-06-1213","volume":"12","author":"A Lipton","year":"2006","unstructured":"Lipton A, Berenson JR, Body JJ et al (2006) Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res 12(20 Pt 2):6209s\u20136212s","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1420_CR5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98(11):1736\u20131740","journal-title":"Br J Cancer"},{"issue":"2","key":"1420_CR6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","volume":"182","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Bosserman L, Gao G et al (2009) Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 182(2):509\u2013515","journal-title":"J Urol"},{"issue":"5","key":"1420_CR7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-007-9061-x","volume":"81","author":"JE Brown","year":"2007","unstructured":"Brown JE, McCloskey EV, Dewar JA et al (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 81(5):341\u2013351","journal-title":"Calcif Tissue Int"},{"issue":"22","key":"1420_CR8","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22):4925\u20134935","journal-title":"J Clin Oncol"},{"issue":"11 Pt 1","key":"1420_CR9","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","volume":"12","author":"RJ Cook","year":"2006","unstructured":"Cook RJ, Coleman R, Brown J et al (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12(11 Pt 1):3361\u20133367","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1420_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1515\/CCLM.1998.154","volume":"36","author":"H Engler","year":"1998","unstructured":"Engler H, Koeberle D, Thuerlimann B et al (1998) Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med 36(11):879\u2013885","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"1420_CR11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","volume":"54","author":"P Garnero","year":"2008","unstructured":"Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54(1):188\u2013196","journal-title":"Clin Chem"},{"issue":"3","key":"1420_CR12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-009-0646-0","volume":"119","author":"FM McCaig","year":"2010","unstructured":"McCaig FM, Renshaw L, Williams L et al (2010) A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 119(3):643\u2013651","journal-title":"Breast Cancer Res Treat"},{"issue":"3A","key":"1420_CR13","first-page":"1491","volume":"25","author":"D L\u00fcftner","year":"2005","unstructured":"L\u00fcftner D, Jozereau D, Schildhauer S et al (2005) PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 25(3A):1491\u20131499","journal-title":"Anticancer Res"},{"issue":"2","key":"1420_CR14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/00365519950185850","volume":"59","author":"MA Diaz-Martin","year":"1999","unstructured":"Diaz-Martin MA, Traba ML, de la Piedra C et al (1999) Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. AScand J Clin Lab Invest 59(2):125\u2013132","journal-title":"AScand J Clin Lab Invest"},{"issue":"1","key":"1420_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s005200050218","volume":"7","author":"D Koeberle","year":"1999","unstructured":"Koeberle D, Bacchus L, Thuerlimann B et al (1999) Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer 7(1):21\u201327","journal-title":"Support Care Cancer"},{"issue":"2","key":"1420_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s005200050025","volume":"8","author":"U Gessner","year":"2000","unstructured":"Gessner U, Koeberle D, Thuerlimann B et al (2000) Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Support Care Cancer 8(2):115\u2013122","journal-title":"Support Care Cancer"},{"issue":"1","key":"1420_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/clinchem\/45.1.47","volume":"45","author":"J Brandt","year":"1999","unstructured":"Brandt J, Krogh TN, Jensen CH et al (1999) Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 45(1):47\u201353","journal-title":"Clin Chem"},{"issue":"3","key":"1420_CR18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","volume":"70","author":"OP Purohit","year":"1994","unstructured":"Purohit OP, Anthony C, Radstone CR et al (1994) High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70(3):554\u2013558","journal-title":"Br J Cancer"},{"issue":"3","key":"1420_CR19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165\u2013176","journal-title":"Cancer Treat Rev"},{"issue":"4A","key":"1420_CR20","first-page":"1853","volume":"27","author":"D Pollmann","year":"2007","unstructured":"Pollmann D, Siepmann S, Geppert R et al (2007) The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27(4A):1853\u20131862","journal-title":"Anticancer Res"},{"key":"1420_CR21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001980070088","volume":"11","author":"A Looker","year":"2000","unstructured":"Looker A, Bauer D, Chesnut C III et al (2000) Clinical use of biochemical markers of bone remodelling: Current status and future directions. Osteoporos Int 11:467\u2013480","journal-title":"Osteoporos Int"},{"issue":"suppl.1","key":"1420_CR22","first-page":"S227","volume":"20","author":"E Leary","year":"2005","unstructured":"Leary E (2005) Serum CTX and P1NP by Roche Elecsys as Theranostics in the Treatment of Osteoporosis. J Bone Mineral Res 20(suppl.1):S227","journal-title":"J Bone Mineral Res"},{"issue":"1","key":"1420_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.1997.15.1.131","volume":"15","author":"J Vinholes","year":"1997","unstructured":"Vinholes J, Guo CY, Purohit OP et al (1997) Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 15(1):131\u2013138","journal-title":"J Clin Oncol"},{"issue":"17","key":"1420_CR24","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","volume":"22","author":"I Mancini","year":"2004","unstructured":"Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22(17):3587\u20133592","journal-title":"J Clin Oncol"},{"issue":"1","key":"1420_CR25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","volume":"165","author":"A Heidenreich","year":"2001","unstructured":"Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165(1):136\u2013140","journal-title":"J Urol"},{"issue":"4","key":"1420_CR26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD et al (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16(4):579\u2013584","journal-title":"Ann Oncol"},{"issue":"5 Suppl 10","key":"1420_CR27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminoncol.2004.07.026","volume":"31","author":"A Heidenreich","year":"2004","unstructured":"Heidenreich A, Ohlmann C, Body JJ (2004) Ibandronate in metastatic bone pain. Semin Oncol 31(5 Suppl 10):67\u201372","journal-title":"Semin Oncol"},{"issue":"6","key":"1420_CR28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90(6):1133\u20131137","journal-title":"Br J Cancer"},{"issue":"3","key":"1420_CR29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","volume":"111","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3):306\u2013312","journal-title":"Pain"},{"issue":"6","key":"1420_CR30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2004.08.016","volume":"46","author":"F Saad","year":"2004","unstructured":"Saad F, Olsson C, Schulman CC (2004) Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46(6):731\u2013739","journal-title":"Eur Urol"},{"issue":"4","key":"1420_CR31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpainsymman.2007.01.001","volume":"33","author":"J Gralow","year":"2007","unstructured":"Gralow J, Tripathy D (2007) Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 33(4):462\u2013472","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"1420_CR32","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P et al (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92(10):1869\u20131876","journal-title":"Br J Cancer"},{"issue":"2","key":"1420_CR33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y et al (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42(2):164\u2013175","journal-title":"Med Care"},{"issue":"1","key":"1420_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-007-9583-y","volume":"108","author":"M Clemons","year":"2008","unstructured":"Clemons M, Dranitsaris G, Ooi W et al (2008) A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 108(1):79\u201385","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1420_CR35","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","volume":"40","author":"IJ Diel","year":"2004","unstructured":"Diel IJ, Body JJ, Lichinitser MR et al (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40(11):1704\u20131712","journal-title":"Eur J Cancer"},{"issue":"6","key":"1420_CR36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3349\/ymj.2007.48.6.1001","volume":"48","author":"SJ Hong","year":"2007","unstructured":"Hong SJ, Cho KS, Cho HY et al (2007) A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. Yonsei Med J 48(6):1001\u20131008","journal-title":"Yonsei Med J"},{"issue":"4","key":"1420_CR37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3816\/SCT.2007.n.016","volume":"4","author":"A Kretzschmar","year":"2007","unstructured":"Kretzschmar A, Wiege T, Al-Batran SE et al (2007) Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1\u00a0year. Support Cancer Ther 4(4):203\u2013210","journal-title":"Support Cancer Ther"},{"issue":"1","key":"1420_CR38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/104990910602300107","volume":"23","author":"K Mystakidou","year":"2006","unstructured":"Mystakidou K, Katsouda E, Parpa E et al (2006) A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. Am J Hosp Palliat Care 23(1):41\u201350","journal-title":"Am J Hosp Palliat Care"},{"issue":"10","key":"1420_CR39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00520-007-0230-2","volume":"15","author":"C Ripamonti","year":"2007","unstructured":"Ripamonti C, Fagnoni E, Campa T et al (2007) Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study. Support Care Cancer 15(10):1177\u20131184","journal-title":"Support Care Cancer"},{"issue":"23","key":"1420_CR40","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","volume":"21","author":"EJ Small","year":"2003","unstructured":"Small EJ, Smith MR, Seaman JJ et al (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21(23):4277\u20134284","journal-title":"J Clin Oncol"},{"issue":"3","key":"1420_CR41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420\u2013432","journal-title":"Ann Oncol"},{"issue":"2","key":"1420_CR42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1592\/phco.27.2.207","volume":"27","author":"JT Sherer","year":"2007","unstructured":"Sherer JT, Adamus AT (2007) Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events. Pharmacotherapy 27(2):207\u2013217","journal-title":"Pharmacotherapy"},{"issue":"8","key":"1420_CR43","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735\u20131744","journal-title":"Cancer"},{"issue":"1","key":"1420_CR44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1):36\u201343","journal-title":"Cancer"},{"issue":"5","key":"1420_CR45","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377\u2013387","journal-title":"Cancer J"},{"issue":"7","key":"1420_CR46","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdm119","volume":"18","author":"JJ Body","year":"2007","unstructured":"Body JJ, Lichinitser M, Tjulandin S et al (2007) Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 18(7):1165\u20131171","journal-title":"Ann Oncol"},{"key":"1420_CR47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.breast.2009.04.002","volume":"18","author":"A Agrawal","year":"2009","unstructured":"Agrawal A, Hannon RA, Cheung KL et al (2009) Bone turnover markers in postmenopausal breast cancer treated with fulvestrant - A pilot study. The Breast 18:204\u2013207","journal-title":"The Breast"},{"issue":"7494","key":"1420_CR48","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.330.7494.769","volume":"330","author":"MC Gainford","year":"2005","unstructured":"Gainford MC, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769\u2013773","journal-title":"BMJ"},{"issue":"2","key":"1420_CR49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S8756-3282(02)00952-3","volume":"32","author":"AM Ahmad","year":"2003","unstructured":"Ahmad AM, Hopkins MT, Fraser WD et al (2003) Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 32(2):170\u2013179","journal-title":"Bone"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1420-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1420-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T22:35:07Z","timestamp":1591742107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1420-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,4]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1420-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,4]]}}}